journal article·2024-09Open access

Engineering supramolecular dynamics of self-assembly and turnover of oncogenic microRNAs to drive their synergistic destruction in tumor models

Daria Chiglintseva, David J. Clarke, Aleksandra Sen'kova, Thomas Heyman, Svetlana Miroshnichenko, Fangzhou Shan, Valentin Vlassov, Marina Zenkova, Olga Patutina, Elena Bichenkova

Biomaterials· Volume 309

Abstract

Rationally-engineered functional biomaterials offer the opportunity to interface with complex biology in a predictive, precise, yet dynamic way to reprogram their behaviour and correct shortcomings. Success here may lead to a desired therapeutic effect against life-threatening diseases, such as cancer. Here, we engineered "Crab"-like artificial ribonucleases through coupling of peptide and nucleic acid building blocks, capable of operating alongside and synergistically with intracellular enzymes (RNase H and AGO2) for potent destruction of oncogenic microRNAs. "Crab"-like configuration of two catalytic peptides ("pincers") flanking the recognition oligonucleotide was instrumental here in providing increased catalytic turnover, leading to ≈30-fold decrease in miRNA half-life as compared with that for "single-pincer" conjugates. Dynamic modeling of miRNA cleavage illustrated how such design enabled "Crabs" to drive catalytic turnover through simultaneous attacks at different locations of the RNA-DNA heteroduplex, presumably by producing smaller cleavage products and by providing toeholds for competitive displacement by intact miRNA strands. miRNA cleavage at the 5'-site, spreading further into double-stranded region, likely provided a synergy for RNase H1 through demolition of its loading region, thus facilitating enzyme turnover. Such synergy was critical for sustaining persistent disposal of continually-emerging oncogenic miRNAs. A single exposure to the best structural variant (Crab-p-21) prior to transplantation into mice suppressed their malignant properties and reduced primary tumor volume (by 85 %) in MCF-7 murine xenograft models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · DNA and Nucleic Acid Chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (88)

Show source-provided references
1. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation10.3389/fendo.2018.00402 ↗
2. An overview of microRNAs: biology, functions, therapeutics, and analysis methods10.1002/jcp.27486 ↗
3. An overview of microRNAs10.1016/j.addr.2015.05.001 ↗
4. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases10.1038/nrd.2016.246 ↗
5. Cancer-associated miRNAs and their therapeutic potential10.1038/s10038-021-00938-6 ↗
6. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges10.1038/aps.2018.30 ↗
7. microRNAs in Parkinson's disease: from pathogenesis to novel diagnostic and therapeutic approaches10.3390/ijms18122698 ↗
8. microRNA dysregulation in neurodegenerative diseases: a systematic review10.1016/j.pneurobio.2019.101664 ↗
9. Role of host and pathogen-derived MicroRNAs in immune regulation during infectious and inflammatory diseases10.3389/fimmu.2019.03081 ↗
10. MicroRNAs in alzheimer's disease: diagnostic markers or therapeutic agents?10.3389/fphar.2019.00665 ↗
11. Antibody–drug conjugates and small molecule–drug conjugates: opportunities and challenges for the development of selective anticancer cytotoxic agents10.1021/acs.jmedchem.5b00457 ↗
12. Diagnosing the decline in pharmaceutical R& D efficiency10.1038/nrd3681 ↗
13. CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo
14. CRISPR/Cas9-mediated noncoding RNA editing in human cancers10.1080/15476286.2017.1391443 ↗
15. Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties10.1073/pnas.1813376116 ↗
16. Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency10.1073/pnas.2016158117 ↗
17. Single shot vs. Cocktail: a comparison of mono- and combinative application of miRNA-targeted mesyl oligonucleotides for efficient antitumor therapy10.3390/cancers14184396 ↗
18. Non-nucleotide modification of anti-miRNA oligonucleotides10.1007/978-1-4939-6563-2_3 ↗
19. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes10.1093/nar/gkg707 ↗
20. The effect of antisense inhibitor of miRNA 106b∼25 on the proliferation, invasion, migration, and apoptosis of gastric cancer cell10.1007/s13277-016-4937-x ↗
21. Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system10.1016/j.jconrel.2018.05.010 ↗
22. Anti-miRNA oligonucleotides: a comprehensive guide for design10.1080/15476286.2018.1445959 ↗
23. Enhanced inhibition of tumorigenesis using combinations of miRNA-targeted therapeutics10.3389/fphar.2019.00488 ↗
24. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells10.1038/nmeth1079 ↗
25. MicroRNA sponges: progress and possibilities10.1261/rna.2414110 ↗
26. miRNA-10b sponge: an anti-breast cancer study in vitro10.3892/or.2016.4596 ↗
27. miRNA oligonucleotide and sponge for miRNA-21 inhibition mediated by PEI-PLL in breast cancer therapy10.1016/j.actbio.2015.07.020 ↗
28. A microRNA 221– and 222–mediated feedback loop maintains constitutive activation of NFκB and STAT3 in colorectal cancer cells10.1053/j.gastro.2014.06.006 ↗
29. Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers10.1016/j.cyto.2016.01.015 ↗
30. Small RNA zippers lock miRNA molecules and block miRNA function in mammalian cells10.1038/ncomms13964 ↗
31. Synthetic circular miR-21 RNA decoys enhance tumor suppressor expression and impair tumor growth in mice10.1093/narcan/zcaa014 ↗
32. Synthetic circular miR-21 sponge as tool for lung cancer treatment10.3390/ijms23062963 ↗
33. Synthetic circular RNA functions as a miR-21 sponge to suppress gastric carcinoma cell proliferation10.1016/j.omtn.2018.09.010 ↗
34. Emerging concepts of miRNA therapeutics: from cells to clinic10.1016/j.tig.2022.02.006 ↗
35. Global analyses of the dynamics of mammalian microRNA metabolism10.1101/gr.251421.119 ↗
36. miRNases: novel peptide-oligonucleotide bioconjugates that silence miR-21 in lymphosarcoma cells10.1016/j.biomaterials.2017.01.018 ↗
37. Catalytic knockdown of miR-21 by artificial Ribonuclease: biological performance in tumor model10.3389/fphar.2019.00879 ↗
38. Dual miRNases for triple incision of miRNA target: design concept and catalytic performance10.3390/molecules25102459 ↗
39. Bulge-forming miRNases cleave oncogenic miRNAs at the central loop region in a sequence-specific manner10.3390/ijms23126562 ↗
40. Strict conformational demands of RNA cleavage in bulge-loops created by peptidyl-oligonucleotide conjugates10.1093/nar/gkaa780 ↗
41. “Bind, cleave and leave”: multiple turnover catalysis of RNA cleavage by bulge–loop inducing supramolecular conjugates10.1093/nar/gkab1273 ↗
42. Peptidyl-oligonucleotide conjugates demonstrate efficient cleavage of RNA in a sequence-specific manner10.1021/acs.bioconjchem.5b00193 ↗
43. Peptide-oligonucleotide conjugates exhibiting pyrimidine-X cleavage specificity efficiently silence miRNA target acting synergistically with RNase H10.1038/s41598-018-33331-z ↗
44. High-throughput analysis reveals rules for target RNA binding and cleavage by AGO210.1016/j.molcel.2019.06.012 ↗
45. Metazoan MicroRNAs10.1016/j.cell.2018.03.006 ↗
46. How complementary targets expose the microRNA 3′ end for tailing and trimming during target-directed microRNA degradation10.1101/sqb.2019.84.039321 ↗
47. Anatomy of four human Argonaute proteins10.1093/nar/gkac519 ↗
48. Silencing of microRNA families by seed-targeting tiny LNAs10.1038/ng.786 ↗
49. Inhibition of gastric tumor cell growth using seed-targeting LNA as specific, long-lasting MicroRNA inhibitors10.1038/mtna.2015.18 ↗
50. RNase T1 mimicking artificial ribonuclease10.1093/nar/gkm143 ↗
51. Use of in vitro 32P labeling in the sequence analysis of nonradioactive tRNAs10.1016/0076-6879(79)59072-7 ↗
52. Real-time quantification of microRNAs by stem-loop RT-PCR10.1093/nar/gni178 ↗
53. Varkonyi-Gasic · 2011 · 145
54. Kinetics of RNA and RNA:DNA hybrid strand displacement10.1021/acssynbio.1c00336 ↗
55. Kinetics of heterochiral strand displacement from PNA–DNA heteroduplexes10.1093/nar/gkab499 ↗
56. Upper rim guanidinocalix[4]arenes as artificial phosphodiesterases10.1021/jo300193y ↗
57. Guanidinium promoted cleavage of phosphoric diesters: kinetic investigations and calculations provide indications on the operating mechanism10.1021/acs.joc.7b01925 ↗
58. Guanidine–guanidinium cooperation in bifunctional artificial phosphodiesterases based on diphenylmethane spacers; gem -dialkyl effect on catalytic efficiency10.1021/jo401085z ↗
59. Structural modifications as tools in mechanistic studies of the cleavage of RNA phosphodiester linkages10.1002/tcr.202200141 ↗
60. Site-selective cleavage of structured RNA by a staphylococcal nuclease-DNA hybrid10.1073/pnas.86.6.1766 ↗
61. From molecular mechanisms to therapeutics: understanding MicroRNA-21 in cancer10.3390/cells11182791 ↗
62. MicroRNA-21: from cancer to cardiovascular disease10.2174/138945010791591403 ↗
63. c-Myc-regulated microRNAs modulate E2F1 expression10.1038/nature03677 ↗
64. MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases10.1007/s11010-011-1052-6 ↗
65. The reactivity of phosphodiester bonds within linear single-stranded oligoribonucleotides is strongly dependent on the base sequence10.1093/nar/30.2.468 ↗
66. The base sequence dependent flexibility of linear single-stranded oligoribonucleotides correlates with the reactivity of the phosphodiester bond10.1039/B302751A ↗
67. Stabilisation of the transition state of phosphodiester bond cleavage within linear single-stranded oligoribonucleotides10.1039/B309828A ↗
68. Predicting stability of DNA duplexes in solutions containing magnesium and monovalent cations10.1021/bi702363u ↗
69. Quantitative prediction of miRNA-mRNA interaction based on equilibrium concentrations10.1371/journal.pcbi.1001090 ↗
70. Modified deoxyoligonucleotides stable to exonuclease degradation in serum10.1093/nar/19.4.747 ↗
71. A direct comparison of anti-microRNA oligonucleotide potency10.1007/s11095-010-0156-0 ↗
72. miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma10.1038/labinvest.2015.105 ↗
73. miR‐17‐5p promotes proliferation and epithelial‐mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 110.1002/jcb.27832 ↗
74. The promising role of miR-21 as a cancer biomarker and its importance in RNA-based therapeutics10.1016/j.omtn.2020.03.003 ↗
75. The MicroRNA family both in normal development and in different diseases: the miR-17-92 cluster
76. MiR-17-5p enhances pancreatic cancer proliferation by altering cell cycle profiles via disruption of RBL2/E2F4-repressing complexes10.1016/j.canlet.2017.09.044 ↗
77. Differential response of normal and transformed mammary epithelial cells to combined treatment of anti-miR-21 and radiation10.1080/09553002.2016.1266057 ↗
78. Selective inhibition of miR-21 by phage display screened peptide10.1093/nar/gkv185 ↗
79. Pre-clinical and clinical importance of miR-21 in human cancers: tumorigenesis, therapy response, delivery approaches and targeting agents10.1016/j.phrs.2022.106568 ↗
80. Structural basis for target-directed MicroRNA degradation10.1016/j.molcel.2019.06.019 ↗
81. Prediction and pan-cancer analysis of mammalian transcripts involved in target directed miRNA degradation10.1093/nar/gkac057 ↗
82. Ultrafast dynamics in DNA: “fraying” at the end of the helix10.1021/ja0582105 ↗
83. Global quantification of mammalian gene expression control10.1038/nature10098 ↗
84. Cotranscriptional events in eukaryotic ribosome synthesis10.1002/wrna.1263 ↗
85. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma10.1016/j.biopha.2018.05.157 ↗
86. Effect of miR-21 on apoptosis in lung cancer cell through inhibiting the PI3K/akt/NF-κB signaling pathway in vitro and in vivo10.1159/000488831 ↗
87. MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer10.1007/s13277-016-5074-2 ↗
88. Therapeutic inhibition of microRNA-21 (miR-21) using locked-nucleic acid (LNA)-anti-miR and its effects on the biological behaviors of melanoma cancer cells in preclinical studies10.1186/s12935-020-01394-6 ↗